# 1 Hyperplex PCR enables the next-generation of wastewater-

## 2 based surveillance systems: long-term SARS-CoV-2 variant

## 3 surveillance in Sweden as a case study

- 4 Ruben R. G. Soares  $d^*$ ; Javier Edo Varg<sup>a</sup>; Attila Szabó<sup>a, c</sup>; Margarita Psallida<sup>d</sup>;
- 5 Pawel Olszewski <sup>d</sup>; Danai V. Nikou <sup>d</sup>; Umear Naseem <sup>d</sup>; Maja Malmberg <sup>b</sup>; Anna J. Székely <sup>a\*</sup>
- <sup>6</sup> <sup>a</sup> Department of Aquatic Sciences and Assessment, Swedish University of Agricultural
- 7 Sciences, Box 7050, 75007, Uppsala, Sweden
- <sup>b</sup> Department of Animal Biosciences, Swedish University of Agricultural Sciences, Box
- 9 7023, 750 07 Uppsala, Sweden
- <sup>c</sup> Institute of Aquatic Ecology, HUN-REN Centre for Ecological Research, Karolina str.
- 11 29., H- 1113 Budapest, Hungary
- <sup>d</sup> Aplex Bio AB, Nobels väg 16, 171 65, Solna, Sweden
- 13
- 14 <sup>\*</sup> Contact authors:
- 15 Ruben R.G. Soares; Nobels väg 16, Solna, Sweden; <u>ruben@aplex.bio</u>
- 16 Anna J. Székely; Lennart Hjelms väg 9, Uppsala, Sweden; <u>anna.szekely@slu.se</u>

17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 18 Abstract

Wastewater-based epidemiology aims at measuring pathogens in wastewater as a means of deriving unbiased epidemiological information at a population scale, ranging from buildings and aircrafts to entire cities or countries. After gaining significant mainstream attention during the SARS-CoV-2 pandemic, the field holds significant promise as a continuous monitoring and early warning system tracking emerging viral variants or new pathogens with pandemic potential.

25 To expand the current toolbox of analytical techniques for wastewater analysis, 26 we explored the use of Hyperplex PCR (hpPCR) to analyse SARS-CoV-2 mutations in 27 wastewater samples collected weekly in up to 22 sites across Sweden between October 28 2022 and December 2023. Approximately 900 samples were tested using a dynamic 29 probe panel with a multiplexity ranging from 10- to 18-plex, continuously adapted within 30 1-2 weeks to quantify relevant mutations of concern over time. The panel simultaneously 31 covered deletions, single nucleotide substitutions, as well as variable regions resorting to 32 probe degeneracy. By analysing all samples in parallel resorting to gold standard methods 33 including qPCR and two different NGS technologies, the performance of hpPCR is herein 34 shown to bridge the gap between these methods by providing (1) systematic single 35 nucleotide sensitivity with a simple probe design, (2) high multiplexity without panel re-36 optimization requirements and (3) 4-5-week earlier mutation detection compared to NGS 37 with excellent quantitative linearity and a good correlation for mutation frequency 38 (r=0.88). Based on the demonstrated performance, the authors propose the combined use 39 of NGS and hpPCR for routine discovery and high-frequency monitoring of key 40 pathogens/variants as a potential alternative to the current analysis paradigm.

41

42

43 Keywords: hpPCR; wastewater-based epidemiology; mutations; monitoring; padlock
44 probes; rolling circle amplification

45

# 47 **1. Introduction**

48 Wastewater-based epidemiology (WBE), although being an 80-year-old concept, only 49 reached the lab bench in the early 2000's and recently catapulted to mainstream attention 50 during the 2020 SARS-CoV-2 pandemic [1] As the name implies, the field aims at analysing wastewater samples for the presence and quantity of infectious agents to derive 51 52 epidemiological information at population level. There is currently an increasing body of 53 evidence showing the potential of this approach as a reliable and intrinsically unbiased 54 proxy of total cases in each population, thus easing the economic and logistical burden of 55 mass population testing [2], [3]. The latter becomes particularly relevant to enable 56 successful implementation of pandemic preparedness systems for national level routine 57 monitoring of circulating and emerging pathogens [4]. This approach has been tested both 58 at city/municipality-level and at smaller scales, such as buildings (e.g. office spaces and 59 airports) and airplanes [5], ultimately allowing to trace the origin of novel mutations to 60 specific sites [6]. All these serve as key examples where a developed WBE toolbox can 61 serve as a key resource in pandemic preparedness by enabling more efficient and 62 information-driven containment policies. However, there are still multiple barriers 63 towards reaching such degree of maturity, ranging from (1) detecting highly diluted and 64 potentially degraded RNA in the PCR inhibitor-rich wastewater matrix, to (2) the 65 challenges in implementing adequate sampling protocols, transport logistics and assay controls to ensure that the measured target concentrations adequately represent the 66 67 population and can be reliably compared between different sampling sites and sampling 68 times [1]. To address these challenges, sensitive, specific, mass deployable, scalable, 69 rapid, and cost-efficient methods allowing high-frequency sampling are in demand to 70 gather and share high volumes of data required to consolidate WBE as a routine 71 surveillance tool.

72 The current analytical toolbox to measure SARS-CoV-2 RNA in wastewater comprises a 73 first concentration and extraction-step, aiming at maximizing RNA titters while reducing 74 the concentration of potential inhibitors [7]. Then, targeted, or non-targeted analytical 75 methods are used for qualitative or quantitative analysis. Targeted methods include 76 quantitative PCR (qPCR) and digital PCR (dPCR) and non-targeted analysis is typically 77 done using next generation sequencing (NGS). Reverse transcription-qPCR (RT-qPCR) 78 is currently the most cost-effective option and provides high sensitivity combined with a 79 wide dynamic range, being the standard workhorse for wastewater monitoring,

80 particularly when measuring total SARS-CoV-2 virus titters targeting conserved 81 sequences [8]. On the other hand, despite increased running costs [9], there is an 82 increasing shift towards ddPCR based on substantial [10], [11], albeit not undisputed [9] 83 evidence of higher sensitivity and resistance to inhibition. However, despite significant 84 efforts to apply both RT-qPCR [12], [13], [14], [15] and dPCR [16], [17], [18], [19] for 85 SARS-CoV-2 variant surveillance using hydrolysis probes, protocol optimization to 86 target point mutations typically requires extensive adjustment of annealing temperatures 87 to avoid false-positive detections [12]. Additionally, locked nucleic acids (LNA) might 88 have to be introduced into the probe sequence to increase specificity [15], and background 89 signals often interfere with the results particularly for high concentrations of off-target 90 sequences (e.g. wild-type sequence) [9]. Furthermore, both methods are limited in the 91 degree of multiplexity per sample, often capped at less than 6 targets per sample which is 92 suboptimal for a broad-scope variant analysis. All these factors cause delays and practical 93 barriers in implementing fit-for-purpose assays for emerging variants, consequently 94 forcing researchers to turn towards targeted NGS [20], [21], [22] despite the substantially 95 higher consumable and labour costs. To address the specificity and multiplexity 96 limitations of RT-qPCR and dPCR, while avoiding the increased costs and complexity of 97 NGS, Hyperplex PCR (hpPCR) integrates RT-PCR, padlock probes (PLPs), rolling circle 98 amplification (RCA) [23] and optically encoded probes [24]. This approach ensures 99 robust single-nucleotide specificity combined with massive multiplexity of more than 100 100 targets per sample through post-amplification optical fluorescence imaging.

101

# 102 2. Results and Discussion

## 103 **2.1. Methodology and study overview**

104 The main goal of this study was to evaluate the performance of Hyperplex PCR (hpPCR) 105 in the context of multiplex targeted quantification of SARS-CoV-2 mutations of concern 106 in wastewater samples. The workflow of Hyperplex PCR is schematized in Figure 1-A 107 and comprises 3 main steps. The first step includes a 1-step RT-PCR amplification of the 108 target regions of interest, padlock probe (PLP) ligation to the target mutations and rolling 109 circle amplification of the ligated probes. The ligation of the panel of PLPs was performed 110 after dilution of the PCR amplicons, allowing for archiving of PCR amplicons and re-111 probing of mutations within the same amplicons. Performing the probing with a ligation 112 reaction instead of typical hybridization-based hydrolysis probes (e.g. TaqMan probes or

113 molecular beacons), particularly when using thermostable ligases ensures systematic and 114 virtually optimization-free single nucleotide specificity under optimized conditions [25]. 115 Each padlock probe contains a proprietary barcode in the backbone (sequence between 116 the left and right arms) resulting in a total length of 96 bp for each probe. The subsequent 117 RCA step generates amplification products of about 1 µm in diameter containing about 118 1-2 thousand copies of the barcode sequence. In the second step, the rolling circle 119 amplification products (RCPs) are captured on a surface and each barcode will be 120 specifically recognized by Nanopixel probes having a unique optical code corresponding 121 to each target barcode of the PLPs. In the final third step, the surface is imaged with 122 fluorescence microscopy and RCPs of each specific optical barcode are counted and 123 normalized to an internal RCP reference to neutralize variation in capture efficiency.

124 Figure 1-B illustrates the collection sites, probe design map within the SARS-CoV-2 125 genome, and sample analysis logistics. From October 2022 to December 2023, 126 approximately 900 wastewater samples were collected weekly from up to 22 wastewater 127 treatment plants across Sweden, including 6 located in Stockholm municipality (Table 128 S7). During the analysis period a total of 36 PLPs were designed targeting 12 RT-PCR 129 amplified regions of the SARS-CoV-2 genome. Three probes were dedicated to internal 130 control targets, namely PMMoV as a marker of human fecal material and N1 (up to 131 w15/2023) or N3 (from w16/2023) as conserved SARS-CoV-2 genes. The remaining 33 132 probes were designed to target key mutations characteristic of emerging SARS-CoV-2 133 variants of concern. Among this probe set, (1) single nucleotide substitutions, (2) 134 deletions and (3) pooled mutation profiling were achieved simultaneously with different 135 probe designs. PLPs for single nucleotide substitutions were preferably designed with the 136 mutation placed on the 3' end, PLPs for deletions were designed with the extremes of the 137 deleted region complementary to each probe arm and pooled mutation profiling 138 (designated as "X" amino acid substitutions in Figure 1-B) was achieved using degenerate 139 bases and common barcodes (corresponding to the same Nanopixel probe) in the PLP 140 backbone. The PCR primers and PLPs included in the analysis were modified throughout 141 the study (Methods section 4.4.1), from initially 10-plex to an 18-plex panel by Summer 142 2023 upon the emergence of the BA.2.86 variant.

Since one of the key objectives of the study was to evaluate if Hyperplex PCR could improve WBE analysis compared to current methodologies, in particular non-targeted approaches, all collected samples were split after extraction and measured in parallel using conventional qPCR and one of two NGS methods, namely optical- (Illumina) and

- 147 semiconductor-based (Ion Torrent) sequencing. (Ion Torrent: w40/2022-w21/2023 and
- 148 w35-36/2023, and Illumina: w22-34/2023 and w37-52/2023). The following subsections
- explore the output of Hyperplex PCR compared to qPCR, and NGS, as well as published
- 150 clinical data to validate its relevance in the context of WBE and future pandemic
- 151 preparedness.
  - Α.

**Hyperplex** PCR





**Figure 1:** Hyperplex PCR workflow and overview of wastewater collection and analysis approach. **A-** Workflow of Hyperplex PCR comprising 3 main analytical steps: (1) amplification of extracted nucleic acids by reverse transcription PCR (RT-PCR), followed by padlock probe (PLP) ligation and re-amplification of the PCR amplicons into rolling circle amplification products (RCPs); (2) Capture of the RCPs on a solid phase with a SLAS format and subsequent

158 hybridization to Nanopixel probes and; (3) Imaging of the Nanopixel-probed RCPs using an 159 epifluorescence microscope, followed by decoding of the Nanopixel optical probes using a 160 proprietary image analysis tool from APLEX Bio which converts the image into RCP counts per 161 PLP target sequence. **B**-Design of long-term study and analytical approach using Hyperplex PCR, 162 qPCR, Illumina and Ion Torrent in parallel for each extracted sample. For Hyperplex PCR, a total 163 of 12 PCR primer pairs and 36 PLPs were designed spanning the entire genome of SARS-CoV-164 2. To adapt to outcompeted and emerging viral variants over time, not all probes were used 165 simultaneously and up to 18-plex target analysis was performed. The "X" in the amino-acid 166 substitution nomenclature refers to multiple mutations being covered by a set of degenerate PLPs 167 encoded by the same Nanopixel probe.

168

# 169 2.2. Hyperplex PCR allows multiplexed relative quantification of at least 18 170 mutations of concern per assay with rapid panel customization

171 The qPCR and hpPCR results obtained for all tested samples are summarized as heat maps in Figure 2. For qPCR the color coding corresponds to concentration of N1 copies 172 normalized to PMMoV. For hpPCR, the results are expressed as relative counts, meaning 173 174 the absolute signal of the assay for a specific target (according to methods section 4.4.3) 175 normalized to the highest absolute signal measured for that same specific target within 176 the entire dataset. This relative normalization was applied since the efficiency of PCR 177 amplification was not calibrated between targets, hence making the absolute counts not comparable between different mutations, particularly those targeting sequences in 178 179 different PCR amplicons, but comparable between different time-points (x-axis) and 180 collection sites (y-axis). While the assay could be designed to provide absolute 181 quantification for each mutation with appropriate internal controls and/or calibration 182 curves, the original aim of the application of the hpPCR method was to complement the 183 ongoing viral quantification efforts with variant composition assessment. Overall, the 184 results in Figure 2 highlight the expanded dataset obtained using hpPCR compared to 185 qPCR, allowing the discrimination of trends for several key mutations of concern 186 according to the recommendations of health authorities at a given time point. Since PLPs 187 ensure reliable single nucleotide specificity with minimal requirements of assay 188 optimization, the targets in the panel can be adapted on demand by including new 189 primers/probes for emerging mutations of concern (solid vertical lines in Figure 2) or 190 excluding primers/probes targeting outcompeted mutations (dashed vertical lines in 191 Figure 2). Upon emergence of a new mutation of interest, the delay to implement a new 192 probe was less than 2 weeks including design (< 1 day), oligo procurement (5-10 days),

193 and PCR primer/PLP mix formulation (< 1 day). Two main waves of infection were 194 observed throughout the testing period, during the winter season of 2022 and 195 autumn/winter season of 2023. During these periods of increased SARS-CoV-2 viral 196 titters in wastewater samples, already prevalent and particularly emerging mutations were 197 also found to peak during those periods, namely S:346X (XBB, BA.2.75), S:K444X 198 (BO.1), S:N460X (BO.1, BA.2.75, XBB) and S:F490S (BJ.1, XBB.1) during the first 199 wave and BA.2.86 mutations (S:483del, S:F157S/R158G, Orf1:A7842G and S:69-70del) 200 during the second wave. Overall, the trends measured for each mutation provided an 201 excellent correlation with trends observed for clinical cases during periods of active 202 clinical monitoring (Figure S1, where the clinical cases for each mutation where estimated 203 using the CoV-Spectrum Portal [26] and the total SARS-CoV-2 incidence published by 204 The Public Health Agency of Sweden - data accessed on March 2023) and successfully 205 allowed the surveillance of re-emerging mutations such as S:K444T from the first clinical 206 cases of DV.7.1 in w30/2023 (asterisk in Figure 2) until virtually zero incidence by 207 w52/2023. Clinical incidence of DV.7.1 was obtained from the CoV-Spectrum portal [26] 208 accessed in March 2024. Considering that upon the decision to implement probes 209 targeting S:F456L, S:Q52H and BA.86 mutations, positive signals were found in most of 210 the tested cities, a retrospective analysis was performed for the 8 sites covering more than 211 100.000 people in the catchment area back to w16/2023 to test the early detection of these 212 variants. The results of this retrospective analysis are described below in section 2.3.



Figure 2: Heatmap plot summarizing the Hyperplex PCR and qPCR results obtained for all tested samples between October 2022 and December 2023 with a frequency of one sample per week for each collection site. qPCR targeted SARS-CoV-2 using the N1 assay until w29/2023 and SCV2

217 onwards. For each target sequence, columns correspond to weekly measurements and rows to 218 each of the 22 collection sites (Table S7). For Hyperplex PCR relative counts refer to signal 219 obtained for each target sequence normalized to the maximum intensity measured for each target 220 among all samples. The blue color code refers to signals below the detection threshold. Variants 221 indicated for each mutation refer to the most prevalent variant associated to the mutation at the 222 time the probes were included in the panel. The asterisk in the S:K444T panel refers to the 223 identification of the first clinical cases of DV.7.1 in Sweden. The qPCR data is duplicated below 224 each column of 10 hpPCR targets for visualization purposes.

225

# 226 2.3. Hyperplex PCR provides mutation frequency quantification comparable to 227 NGS with significantly higher sensitivity

228 Expanding on the quantitative capabilities of hpPCR beyond the relative quantification 229 of target mutations over time in multiple sites, additional probes targeting the wild-type 230 sequence of specific target mutations were added to evaluate the quantification of 231 mutation frequency (MF). By quantifying MF it becomes possible to compare the 232 prevalence of different target mutations by having the total virus (Wt plus Mut sequences) 233 as internal control. In this case, two gold standard NGS methods typically used for 234 wastewater analysis, namely Illumina and Ion Torrent were used to benchmark the MF 235 output of the hpPCR assay focusing on samples collected around the period of wave 1. 236 The MF quantification concept and summary of results are shown in Figure 3-A. 237 According to the example schematics and imaging example of 2-plex results for mutation 238 S:R346T, two uniquely barcoded PLPs are used to target the wild-type (G22599) or 239 mutated sequences (G22599C). The plots highlight the following three key observations. 240 (1) A good correlation of hpPCR and NGS when measuring MF over time for each of the 241 four target mutations was observed, here tested for 2 different major populational centers, 242 namely Uppsala and Malmö covering 191 000 and 356 000 people in the catchment area, 243 respectively. Importantly, both measurements agree with the proportion of SARS-CoV-2 244 clinical samples found with these mutations in Sweden during this period (Figure S2). (2) 245 Spiking known mixtures of synthetic amplicons containing each of the target mutations, 246 hpPCR provides an excellent linearity ( $R^2=0.99$ ) and agreement between expected and 247 observed MF values. (3) Pooling all data obtained for both Uppsala and Malmö samples 248 between w42/2022 and w48/2022, a Pearson correlation coefficient of 0.88 was obtained 249 between the MF output of hpPCR and NGS. Overall, these observations indicate that 250 hpPCR can serve as a viable alternative to NGS for the targeted quantification of point

251 mutation frequency in wastewater. Furthermore, hpPCR was further compared with NGS 252 concerning sensitivity to allow early detection of emerging mutations of concern 253 according to the results in Figure 3-B. Using hpPCR it was systematically possible to 254 detect positivity for emerging mutations 4 to 5 weeks earlier compared to NGS for 3 key 255 mutations characteristic of highly relevant VOCs, namely XBB 1.5 and EG.5 and a set of 256 mutations characteristic of BA.2.86. Remarkably, the readout using hpPCR provided a 257 superior correlation with clinical incidence and early detection when mutation specific 258 incidence represented less than 2% of the total SARS-CoV-2 clinical cases. In the case of 259 BA.2.86, which had several differentiating characteristic mutations relative to other 260 coexisting XBB and BA.5-descendant variants, based on early sequencing data from 261 Swedish patients, only a small subset of 4 mutations were selected for monitoring using 262 hpPCR. Nevertheless, even considering all BA.2.86 characteristic mutations measured 263 using NGS, hpPCR still provided a 3-week earlier detection targeting 4 mutations within 264 the same list of BA2.86 characteristic mutations considered for NGS positivity (Figure 265 S3, Table S6). Interestingly, two samples with at least 3 key mutations of BA.2.86 were 266 found in w20 and w21, in line with the results of NGS considering all BA.2.86 mutations, 267 albeit for different targets and sites (Figure S3, Table S6). Ultimately, combining the 268 possibility of rapidly implementing probes with NGS-grade specificity but having a 269 sensitivity significantly higher than NGS, hpPCR intrinsically enables earlier detection 270 of targets than currently available targeted and non-targeted gold standard methods.



271

272 Figure 3: Benchmarking of quantitative performance (A) and sensitivity (B) of Hyperplex PCR 273 against next-generation sequencing (NGS). A- Conceptual schematic and demonstration of 274 Hyperplex PCR used to quantify mutation frequency of target single nucleotide substitutions, 275 namely M:D3N (G26529A), S:R346T (G22599C), S:N460K (T22942G) and S:K4444T 276 (A22893C). Two probes with different Nanopixel barcodes were used for each target mutation, 277 one targeting the wild-type sequence and the other the mutated sequence. For Hyperplex PCR, 278 the mutation frequency is calculated as the ratio of counts (RCPs) for the mutant sequence to 279 those of the wild-type sequence. The plot showing expected vs observed mutant frequency was 280 obtained using synthetic PCR amplicons (ssDNA) spiked in solution. The plot showing 281 correlation between hpPCR and NGS mutation frequency was obtained by testing wastewater 282 samples (w42/2022 to w48/2022) targeting M:D3, S:N460, S:R346 and S:K444. B- Early 283 detection of mutations and variants of concern using Hyperplex PCR vs NGS. S:F486P, S:F456L 284 and S:Q52H were characteristic of variants XBB 1.5, EG.5 and EG.5.1 when measurements were 285 initiated. Tested mutations for BA.2.86 include S:483del, S:F157S/R158G, Orf1:A7842G and 286 S:69-70del. NGS data refers to the same mutations targeted by Hyperplex PCR. The y axis refers 287 to different collection sites as follows: 1- Göteborg, 2- Helsingborg, 3- Malmö, 4- Örebro, 5-288 Stockholm-Käppala, 6- Umeå, 7- Uppsala, 8- Västerås. The heatmap below each chart refers to

289 the fraction of clinical samples collected in Sweden found to be positive for each of the target 290 mutations under analysis.

291

# **3.** Conclusions

293 Despite the mounting evidence of the potential of WBE for surveillance of present and 294 future pathogen outbreaks and pandemics, the field is still in its infancy with regards to 295 method and output standardization. The current typical WBE approach is schematized in 296 Figure 4 according to alternative 1 where surveillance typically focuses on quantitative 297 monitoring of a limited number of pathogens of interest using target specific qPCR or 298 dPCR. For the surveillance of variants and mutations, this is complemented either by 299 NGS, which is typically successful only in case of sufficiently high titers, or alternatively, 300 by individual mutation specific qPCR or dPCR assays. In this approach there is often a 301 dilemma between reagent and labor cost-effectiveness and necessary performance 302 including the optimization of qPCR or dPCR assays for novel targets, which often 303 culminates with researchers circling back to costly NGS, particularly when several point 304 mutations, become targets of interest as is the case for most SARS-CoV-2 viral variants. 305 Alternatively, Hyperplex PCR is herein demonstrated as a powerful tool enabling 306 affordable quantitative and qualitative high-frequency multi-pathogen wastewater 307 monitoring, deployable in virtually any research lab. As demonstrated here has a 308 performance competitive with state-of-the-art NGS methods, the possibility of rapidly 309 including new probes on-demand and a simple workflow with results from extracted RNA 310 within one workday. Towards enabling a next-generation single-method surveillance 311 approach, Hyperplex PCR thus successfully fills the bioanalytical method gap between 312 qPCR/dPCR and NGS, upgrading the current WBE analytical toolbox by providing: (1) 313 High multiplexity per sample with single nucleotide specificity, (2) NGS-grade mutation 314 frequency quantification with a good correlation (r = 0.88) extremely high linearity ( $R^2 >$ 315 0.99), (3) 4-weeks+ early detection of variants of concern demonstrated vs sequencing, 316 (4) Panel customization with new probes within 2 weeks without panel re-optimization. 317 Based on the results of the long-term study reported herein, the authors believe that 318 hpPCR, particularly upon maximization of multiplexity towards the theoretical limits of 319 100+ target sequences and complemented with open data platforms for rapid probe design and panel customization has the potential to become a gold-standard for sustainable and 320 321 standardized WBE.



322

Figure 4: Current approach typically used for WBE during and after the SARS-CoV-2 pandemic (Alt.1) resorting to qPCR, dPCR and NGS for high-frequency monitoring and proposed alternative approach (Alt. 2) using only hpPCR. The delay until actionable results includes the time to design and validate new primers/probes for emerging mutations/variants in the case of qPCR/dPCR and/or the time to select the ideal method among qPCR, dPCR and NGS to strike an adequate balance between sensitivity and specificity of mutation identification within a certain setting.

330

# **331 4. Methods**

## **332 4.1. Wastewater sample collection and extraction**

For each site, we collected weekly samples of untreated wastewater integrated over a single day (24 hours) using flow-compensated samplers. All measurements represent only one day except for Uppsala, where daily samples were combined flow-proportionally into one composite sample representing one week. The processing of samples followed the protocols outlined in Isaksson et al. [27] involving the concentration and extraction of viral genomic material using the Maxwell RSC Enviro TNA kit (Promega). All nucleic acid extracts were stored at -80 °C until further processing.

340

#### 342 4.2. qPCR quantification of SARS-CoV-2 and PMMoV

The absolute quantification of SARS-CoV-2 genome copy numbers followed the methodology outlined in Isaksson et al. [27]. Until w31/2023 quantification was performed using the SARS-CoV-2 specific N1 assay [28] while from w32/2023 the Flu SC2 Multiplex Assay (CDC) was utilized. To account for variations in population size and wastewater flow, the SARS-CoV-2 genome copy numbers were normalized to pepper mild mottle virus (PMMoV) copy numbers. PMMoV quantification followed a modified version of the assay described by Zhang et al [29]

350

## 351 **4.3. Next generation sequencing (NGS)**

The generated total nucleic acid (TNA) extracts were sequenced either on Thermo Fisher's Ion Torrent System (w40/2022-w21/2023 and w35-36/2023), or on Illumina (w22-34/2023 and w37-52/2023).

355

## 356 4.3.1. Ion torrent sequencing

357 The sequencing libraries for Ion Torrent were prepared from the extracted total nucleic 358 acids were prepared using the Ion AmpliSeq<sup>™</sup> SARS-COV-2 Insight Research Assay (Thermo Fisher Scientific) and the SuperScript<sup>TM</sup> VILO<sup>TM</sup> cDNA Synthesis Kit (Thermo 359 360 Fisher), following the manufacturer's protocols "Reverse transcribe RNA with the 361 SuperScript<sup>™</sup> VILO<sup>™</sup> cDNA Synthesis Kit" (Thermo Fisher) and "Prepare libraries on 362 the Ion Chef<sup>TM</sup> Instrument" (Thermo Fisher) with the Ion Chef System. Sequencing was 363 conducted on the Ion S5 XL System (Thermo Fisher) by multiplexing using Torrent Suite 364 Software version 5.16.1 as per to the manufacturer's instructions (Thermo Fisher). The 365 generated sequence data were filtered, aligned to the manufacturer's references 366 (Ion AmpliSeq SARS-CoV-2-Insight Reference), and used to generate mutation 367 frequency tables for variant detection using the manufacturer's analysis pipeline in 368 Torrent Suite 5.16 (Thermo Fisher, # MAN0017972 Rev B.0, Ch 12). Library 369 preparation, Ion Torrent sequencing, and sequence analyses were carried out at the 370 National Genomics Infrastructure (NGI) at Science for Life Laboratory, Uppsala, 371 Sweden.

372

## 373 4.3.1. Illumina sequencing

For the Illumina sequencing, DNAse treatment (DNase I, Amplification Grade,Invitrogen) was performed to reduce unspecific amplification before library preparation

376 by the COVIDSeq Assay kit (Illumina). Samples from weeks 22, 23, 33, and 34/2023 377 were amplified using the Artic V4.1 NCOV-2019 Panel primers (IDT DNA), while the 378 remaining samples sequenced by Illumina technology were amplified using the Artic 379 V5.3.2 NCOV-2019 Panel primers (IDT DNA). The resulting libraries were sequenced 380 either on the Illumina MiSeq platform using the MiSeq Reagent Kit v3 2 x 76 (150-cycle) 381 (Illumina) (w22-34/2023 and w40/2023), or the Illumina NextSeq 550 platform using the 382 NextSeq Reagent Kit 500/550 High Output Kit v2 2 x 74 (150-cycle) (Illumina) (w37-39/2023 and w41-52/2023). The generated sequence data were processed and used to 383 384 generate mutation frequency tables for variant detection using variant quantification in 385 sewage pipeline designed for robustness (VaQuERo.v2) [2]. Library preparation, 386 Illumina sequencing, and sequence analyses were carried at the Swedish University of 387 Agriculture Sciences (SLU).

388

## 389 4.4. Single-reaction 18-plex mutation detection with Hyperplex PCR

The Hyperplex PCR reaction comprises 3 main steps, (1) PCR amplification, PLP ligation and RCA; (2) RCP capture and probing with Nanopixel probes; (3) Imaging of the surface using a fluorescence microscope. The amplification, capture and labelling protocol was performed according to instructions of a custom Hyperplex PCR kit assembled by APLEX Bio including the PCR primers and PLP sequences listed in Table 1.

395

#### 396 4.4.1. Probe design, PCR amplification, PLP ligation and RCA

397 To maximize PCR efficiency, all PCR primers according to Table S1 were designed to 398 generate amplicons with less than 250 bp and having within 5% CV of melting 399 temperature averaging 63 °C. Reference sequences for each target mutation and/or variant 400 were obtained via the European COVID-19 Data Portal and the GISAID initiative [30]. 401 Depending on sequence availability at the date probes were included in the panel, 15 to 402 200 sequences from Swedish patients were aligned and used for primer and probe design. 403 RT-PCR amplification was performed by combining 2 µL of extracted nucleic acids with 404 8 μL a master mix containing all relevant primers for the targets under analysis. Final 405 primer concentrations were between 50 and 150 nM for the forward primers and 67 to 406 300 nM for the reverse primers according to Tables S2, S3, S4 and S5. The mix was then 407 subjected to the following temperatures using a thermal cycler: 25°C for 2 min, 50°C for 408 15 min, 95°C for 2 min, followed by 40 cycles of [95°C for 3 sec, 60°C for 1 min]. After 409 PCR, the amplicons were diluted with 190 µL DNase/RNase-free water water and 0.5 µL

410 of the diluted mixture were combined with 19.5 µL of Ligation mixture in a separate PCR 411 tube, comprising the mix of PLPs (50 pM to 1 nM each final concentration), ligation 412 buffer and hpPCR Ligase. For PLP ligation, the mixture was placed in the thermocycler 413 and subjected to 95 °C for 20 s and 60 °C for 30 min. 10 µL of RCA master mix containing 414 hpPCR polymerase were then added to the 20 µL ligation mix and subjected to an 415 additional 2 hours at 37 °C, followed by enzyme inactivation at 60 °C for 20 min. All 416 temperature cycling and incubation steps were performed in a Bio-Rad T100 thermal 417 cycler with default temperature ramp conditions.

418

## 419 4.4.2. RCP capture and probing with Nanopixels

420 After RCA, 2.5 µL of the RCP solution was combined with 50 µL of capture buffer 421 containing an RCP reference. The RCP reference serves as an internal control to 422 normalize the capture efficiency of RCPs on the surface. 40 µL of this mix were then 423 transferred into the wells of the slide frame mounted on the capture slide provided in the 424 kit, followed by incubation for 5 min at room temperature. Afterwards, 100  $\mu$ L of absolute 425 EtOH were added to each well on top of the capture solution and all contents were 426 subsequently discarded. The wells were then washed twice with wash buffer, followed 427 by 50  $\mu$ L of blocker buffer which was left to incubate 5 min at room temperature. The 428 solution was then removed and 40 µL of labelling master mix containing the probes were 429 added. After 60 min incubation at 37 °C using an incubator oven (Memmert BE200), the 430 solution was removed, each well washed four times with 50 µL wash buffer, the slide 431 frame was disassembled and finally mounted using antifade solution (SlowFade<sup>TM</sup> 432 Diamond Antifade Mountant, Thermo Fisher Scientific).

433

## 434 **4.4.3. Fluorescence microscopy imaging**

435 The microscope used for imaging was a Zeiss Axio Imager 2 equipped with a Hamamatsu 436 Orca Fusion sCMOS camera, a Colibri 7 solid-state light source, a 20x Plan-Apochromat 437 20x/0.8 M27 objective and the following emission filter sets from CHROMA: 525/50 BP, 438 605/52 BP, 690/50 BP, 785/25 BP. Image acquisition was performed with 9 tiles per 439 sample. Analysis of the raw czi files was performed using a proprietary software tool 440 from APLEX Bio including the following general functions: (1) image cropping and 441 background subtraction, (2) channel alignment, (3) segmentation, (4) spot processing and 442 extraction, (5) Nanopixel decoding algorithm and (6) output of counts per color code 443 normalized to an internal reference. For all target mutations, the signal was corrected

444 (cutoff baseline) using an internal control sample containing 1.000 copies/µL of wild-

445 type SARS-CoV-2 IVT RNA (Twist Bioscience Viral Control 2, Wuhan-Hu-1,

446 MN908947.3). All signals above the detection threshold are higher than the average

447 signal of the control plus  $3.29 \times SD$  (n=4).

448

# 449 Acknowledgements

450 The data handling was enabled by resources provided by the National Academic 451 Infrastructure for Supercomputing in Sweden (NAISS), partially funded by the Swedish 452 Research Council through grant agreement no. 2022-06725. Ion Torrent sequencing was 453 performed by the SNP&SEQ Technology Platform in Uppsala. The facility is part of the 454 National Genomics Infrastructure (NGI) Sweden and Science for Life Laboratory. The 455 SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and 456 Alice Wallenberg Foundation. This work was funded by governmental grants provided 457 to the Public Health Agency of Sweden for assignment S2022/04841. We further 458 acknowledge the Public Health Agency of Sweden for contributions to padlock probe 459 target design. U.N. and R.S. are co-inventors of the hpPCR methodology according to 460 patent application WO/2021/206614. U.N. holds shares in Aplex Bio AB. Other authors 461 declare no competing financial interests.

462

# 463 **References**

- 464 [1] H. R. Safford, K. Shapiro, and H. N. Bischel, 'Wastewater analysis can be a
  465 powerful public health tool—if it's done sensibly', *Proceedings of the National*466 *Academy of Sciences of the United States of America*, vol. 119, no. 6. National
  467 Academy of Sciences, Feb. 08, 2022. doi: 10.1073/pnas.2119600119.
- 468 [2] F. Amman *et al.*, 'Viral variant-resolved wastewater surveillance of SARS-CoV-2
  469 at national scale', *Nat Biotechnol*, vol. 40, no. 12, pp. 1814–1822, Dec. 2022, doi: 470 10.1038/s41587-022-01387-y.
- 471 [3] X. Li *et al.*, 'Wastewater-based epidemiology predicts COVID-19-induced weekly
  472 new hospital admissions in over 150 USA counties', *Nat Commun*, vol. 14, no. 1,
  473 Dec. 2023, doi: 10.1038/s41467-023-40305-x.
- 474 [4] M. J. Wade, J. T. Bunce, S. Petterson, C. Ferguson, N. C. del Campo, and E.
  475 Gaddis, 'Editorial: Wastewater-based epidemiology at the frontier of global public
  476 health', *J Water Health*, Feb. 2023, doi: 10.2166/wh.2023.001.
- 477 [5] K. Farkas *et al.*, 'Wastewater-based monitoring of SARS-CoV-2 at UK airports
  478 and its potential role in international public health surveillance', *PLOS Global*

479 *Public Health*, vol. 3, no. 1, p. e0001346, Jan. 2023, doi: 10.1371/journal.pgph.0001346.

- 481 [6] M. M. Shafer *et al.*, 'Tracing the origin of SARS-CoV-2 omicron-like spike
  482 sequences detected in an urban sewershed: a targeted, longitudinal surveillance
  483 study of a cryptic wastewater lineage', *Lancet Microbe*, Mar. 2024, doi:
  484 10.1016/S2666-5247(23)00372-5.
- 485 [7] S. E. Philo *et al.*, 'A comparison of SARS-CoV-2 wastewater concentration
  486 methods for environmental surveillance', *Science of the Total Environment*, vol.
  487 760, Mar. 2021, doi: 10.1016/j.scitotenv.2020.144215.
- 488 [8] M. Perez-Zabaleta et al., 'Long-term SARS-CoV-2 surveillance in the wastewater 489 of Stockholm: What lessons can be learned from the Swedish perspective?', 490 Science of the Total Environment, vol. Feb. 2023. 858, doi: 491 10.1016/j.scitotenv.2022.160023.
- 492 [9] K. Farkas *et al.*, 'Rapid Assessment of SARS-CoV-2 Variant-Associated
  493 Mutations in Wastewater Using Real-Time RT-PCR', *Microbiol Spectr*, vol. 11,
  494 no. 1, Feb. 2023, doi: 10.1128/spectrum.03177-22.
- W. Ahmed *et al.*, 'Comparison of RT-qPCR and RT-dPCR Platforms for the Trace
  Detection of SARS-CoV-2 RNA in Wastewater', *ACS ES and T Water*, vol. 2, no.
  11, pp. 1871–1880, Nov. 2022, doi: 10.1021/acsestwater.1c00387.
- 498 J. Ding, X. Xu, Y. Deng, X. Zheng, and T. Zhang, 'Comparison of RT-ddPCR and [11] 499 RT-qPCR platforms for SARS-CoV-2 detection: Implications for future outbreaks 500 of infectious diseases', Environ Int, vol. 183, Jan. 2024, doi: 501 10.1016/j.envint.2024.108438.
- 502 [12] Y. Liu *et al.*, 'Multiplex Assays Enable Simultaneous Detection and Identification
  503 of SARS-CoV-2 Variants of Concern in Clinical and Wastewater Samples', ACS
  504 Measurement Science Au, vol. 3, no. 4, pp. 258–268, Aug. 2023, doi:
  505 10.1021/acsmeasuresciau.3c00005.
- 506 B. Malla, O. Thakali, S. Shrestha, T. Segawa, M. Kitajima, and E. Haramoto, [13] 507 'Application of a high-throughput quantitative PCR system for simultaneous 508 monitoring of SARS-CoV-2 variants and other pathogenic viruses in wastewater', 509 853, of the Total Environment, Science vol. Dec. 2022, doi: 10.1016/j.scitotenv.2022.158659. 510
- 511 [14] M. Fuzzen *et al.*, 'An improved method for determining frequency of multiple
  512 variants of SARS-CoV-2 in wastewater using qPCR assays', *Science of the Total*513 *Environment*, vol. 881, Jul. 2023, doi: 10.1016/j.scitotenv.2023.163292.
- 514 [15] J. Ding, X. Xu, Y. Deng, X. Zheng, and T. Zhang, 'Circulation of SARS-CoV-2
  515 Omicron sub-lineages revealed by multiplex genotyping RT-qPCR assays for
  516 sewage surveillance', *Science of the Total Environment*, vol. 904, Dec. 2023, doi:
  517 10.1016/j.scitotenv.2023.166300.
- 518 [16] L. Heijnen, G. Elsinga, M. de Graaf, R. Molenkamp, M. P. G. Koopmans, and G.
   519 Medema, 'Droplet digital RT-PCR to detect SARS-CoV-2 signature mutations of

- variants of concern in wastewater', *Science of the Total Environment*, vol. 799,
  Dec. 2021, doi: 10.1016/j.scitotenv.2021.149456.
- 522 [17] E. G. Lou *et al.*, 'Direct comparison of RT-ddPCR and targeted amplicon
   523 sequencing for SARS-CoV-2 mutation monitoring in wastewater', *Science of the* 524 *Total Environment*, vol. 833, Aug. 2022, doi: 10.1016/j.scitotenv.2022.155059.
- J. Ho, C. Stange, R. Suhrborg, C. Wurzbacher, J. E. Drewes, and A. Tiehm,
  'SARS-CoV-2 wastewater surveillance in Germany: Long-term RT-digital droplet
  PCR monitoring, suitability of primer/probe combinations and biomarker
  stability', *Water Res*, vol. 210, Feb. 2022, doi: 10.1016/j.watres.2021.117977.
- 529 [19] S. Wurtzer *et al.*, 'From Alpha to Omicron BA.2: New digital RT-PCR approach
  530 and challenges for SARS-CoV-2 VOC monitoring and normalization of variant
  531 dynamics in wastewater', *Science of the Total Environment*, vol. 848, Nov. 2022,
  532 doi: 10.1016/j.scitotenv.2022.157740.
- 533 [20] M. Kuroiwa *et al.*, 'Targeted amplicon sequencing of wastewater samples for
  534 detecting SARS-CoV-2 variants with high sensitivity and resolution', *Science of*535 *the Total Environment*, vol. 893, Oct. 2023, doi: 10.1016/j.scitotenv.2023.164766.
- 536 [21] G. La Rosa *et al.*, 'Wastewater surveillance of SARS-CoV-2 variants in October–
  537 November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the
  538 BQ.1 lineage', *Science of the Total Environment*, vol. 873, May 2023, doi:
  539 10.1016/j.scitotenv.2023.162339.
- 540 [22] F. Cancela *et al.*, 'Wastewater surveillance of SARS-CoV-2 genomic populations
  541 on a country-wide scale through targeted sequencing', *PLoS One*, vol. 18, no. 4
  542 April, Apr. 2023, doi: 10.1371/journal.pone.0284483.
- [23] R. R. G. Soares, N. Madaboosi, and M. Nilsson, 'Rolling Circle Amplification in Integrated Microsystems: An Uncut Gem toward Massively Multiplexed Pathogen Diagnostics and Genotyping', *Acc Chem Res*, vol. 54, no. 21, pp. 3979–3990, Nov. 2021, doi: 10.1021/acs.accounts.1c00438.
- 547 [24] U. NASEEM and R. R. G. SOARES, 'A METHOD FOR MULTIPLEXED
  548 DETECTION OF A PLURALITY OF TARGET BIOMOLECULES',
  549 WO/2021/206614, Oct. 14, 2021
- 550 [25] G. J. S. Lohman *et al.*, 'A high-throughput assay for the comprehensive profiling
  551 of DNA ligase fidelity', *Nucleic Acids Res*, vol. 44, no. 2, p. e14, Jan. 2016, doi:
  552 10.1093/nar/gkv898.
- 553 [26] C. Chen *et al.*, 'CoV-Spectrum: Analysis of globally shared SARS-CoV-2 data to
  554 identify and characterize new variants', *Bioinformatics*, vol. 38, no. 6, pp. 1735–
  555 1737, Mar. 2022, doi: 10.1093/bioinformatics/btab856.
- 556 [27] F. Isaksson, L. Lundy, A. Hedström, A. J. Székely, and N. Mohamed, 'Evaluating 557 the Use of Alternative Normalization Approaches on SARS-CoV-2 558 Concentrations in Wastewater: Experiences from Two Catchments in Northern 559 Sweden', Environments - *MDPI*, vol. 9, no. 3, Mar. doi: 2022, 560 10.3390/environments9030039.

- 561 [28] C. B. F. Vogels *et al.*, 'Analytical sensitivity and efficiency comparisons of SARS562 CoV-2 RT–qPCR primer–probe sets', *Nat Microbiol*, vol. 5, no. 10, pp. 1299–
  563 1305, Oct. 2020, doi: 10.1038/s41564-020-0761-6.
- 564 [29] T. Zhang *et al.*, 'RNA viral community in human feces: Prevalence of plant
  565 pathogenic viruses', *PLoS Biol*, vol. 4, no. 1, pp. 0108–0118, Jan. 2006, doi:
  566 10.1371/journal.pbio.0040003.
- 567 [30] S. Elbe and G. Buckland-Merrett, 'Data, disease and diplomacy: GISAID's
  568 innovative contribution to global health', *Global Challenges*, vol. 1, no. 1, pp. 33–
  569 46, Jan. 2017, doi: 10.1002/gch2.1018.